Business
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the
About this update from Polaryx Therapeutics, Inc.
[{"type":"text","content":"PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announced that shares of the Company’s common stock will start trading today on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “PLYX”. “We are pleased to announce that Polaryx’s common stock will begin trading on the Nasdaq Stock Market today,” said Alex Yang, Polaryx’s Chairman and Chief Executive Officer. “This listing is a notable milestone that opens a new and exciting chapter in our development, and we look forward to the many opportunities that lie ahead as we work to develop therapies for devastating rare orphan lysosomal disorders. This achievement is also an important testament to the dedication and hard work of the entire Polaryx team.” “Polaryx is embarking on a pivotal and promising phase especially due to SOTERIA, our single arm, open-label Phase 2 trial with a planned launch in the first half of 2026. SOTERIA will assess our lead drug candidate PLX-200’s safety, tolerability, and clinical activity for multiple indications within lysosomal storage disorder in a basket trial and represents a particularly unique, powerful and resource-efficient trial design and corporate catalyst.” Maxim Group LLC acted as the exclusive financial advisor to Polaryx in connection with the direct listing. Gibson, Dunn & Crutcher LLP served as legal advisor and Brownstein Hyatt Farber Schreck, LLP served as Nevada counsel. About the SOTERIA Trial SOTERIA is a Phase 2, open-label, single arm trial intended to assess the safety, tolerability, and clinical activity of Polaryx’s lead drug candidate, PLX-200, in CLN2, CLN3, Krabbe disease, and Sandhoff disease, four different LSDs whose patient populations Polaryx believes represent approximately one quarter of the LSD population. SOTERIA is designed to be flexible, resource-efficient, and provide important data and information important to PLX-200’s future clinical development. Polaryx received a safe to proceed letter in October 2025 from the FDA and plans to initiate SOTERIA in the first half of 2026 in trial sites in the United States as well as in Europe and Asia or other foreign juri...